ReviewIranian journal of pathology2026
Prognosis of Acute Myeloid Leukemia Based on TP53 Mutation Among Adult Patients: A Systematic Review and Meta-Analysis.
Review in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Acute Myeloid Leukemia (AML) is a biologically diverse malignancy influenced by genetic abnormalities, with TP53 mutations playing a key role. Found in 5-10% of de novo AML and more common in therapy-related and secondary AML, TP53 mutations correlate with poor prognosis, chemoresistance, and reduced survival due to defective apoptosis and increased leukemic proliferation. These mutations often coexist with complex karyotypes and are more frequent in older patients, highlighting the need for improved prognostic tools and targeted therapies. This systematic review assessed the prognostic impact of TP53 mutations on overall survival (OS) and relapse-free survival (RFS) in adult AML. Methods: Following PRISMA guidelines, PubMed, Scopus, and Web of Science were searched through January 2025 for studies reporting OS and/or RFS by TP53 mutation status in adult AML. Data on study design, patient demographics, mutation frequency, and outcomes were extracted. Pooled hazard ratios (HRs) for OS and RFS were calculated using a random-effects model. Results: A total of 65 studies comprising over 6,000 adult AML patients were included in this systematic review and meta-analysis. The pooled HR for OS in TP53-mutated patients was 2.22 (95% CI: 2.08-2.37), indicating significantly worse survival than wild-type patients. For RFS, the pooled HR was 2.25 (95% CI: 1.98-2.56), reflecting a higher relapse risk. Heterogeneity was moderate for OS (I²=71%, p<0.01) and low for RFS (I²=0%, p=0.58). Conclusion: TP53 mutations strongly predict poorer overall and relapse-free survival in adult AML, supporting their integration into clinical risk models and emphasizing the need for novel therapeutic approaches in this high-risk subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.